varespladib has been researched along with Arteriosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chouinard, ML; Christie, RM; Eacho, PI; Fraser, H; Gould, KE; Hislop, C; Reidy, CA; Rick, HL; Trias, J | 1 |
| Gelb, MH; Rosenson, RS | 1 |
1 review(s) available for varespladib and Arteriosclerosis
| Article | Year |
|---|---|
Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.
Topics: Acetates; Animals; Arteriosclerosis; Disease Progression; Humans; Indoles; Inflammation; Keto Acids; Lipoproteins; Mice; Oxidative Stress; Phospholipases A2, Secretory; Phospholipids | 2009 |
1 other study(ies) available for varespladib and Arteriosclerosis
| Article | Year |
|---|---|
Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
Topics: Acetates; Aneurysm; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Atherosclerosis; Blood Proteins; Cholesterol; Group II Phospholipases A2; Humans; Indoles; Keto Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Phospholipases A2, Secretory | 2009 |